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SUMMARY
Protein acetylation has emerged as a major mechanism in regulating cellular metabolism. Whereas
most glycolytic steps are reversible, the reaction catalyzed by pyruvate kinase is irreversible and
the reverse reaction requires phosphoenolpyruvate carboxykinase (PEPCK1) to commit for
gluconeogenesis. Here we show that acetylation regulates the stability of the gluconeogenic rate
limiting enzyme PEPCK1, thereby modulating cellular response to glucose. High glucose
destabilizes PEPCK1 by stimulating its acetylation. PEPCK1 is acetylated by the P300
acetyltransferase and this acetylation stimulates the interaction between PEPCK1 and UBR5, a
HECT domain containing E3 ubiquitin ligase, therefore promoting PEPCK1 ubiquitinylation and
degradation. Conversely, SIRT2 deacetylates and stabilizes PEPCK1. These observations
represent an example that acetylation targets a metabolic enzyme to a specific E3 ligase in
response to metabolic condition changes. Given that increased levels of PEPCK is linked with
type II diabetes, this study also identifies potential therapeutic targets for diabetes.
INTRODUCTION
Metabolic enzymes are regulated by various mechanisms such as transcription, post
translational modifications (PTM), and allosteric regulation. The role of PTM in metabolism
regulation has received close attention not only because its ability of acutely responding to
changes in cellular metabolic status but also its regulation by upstream signaling pathways.
Phosphorylation was first discovered in the study of metabolic enzymes and plays a very
broad role in metabolic control through mostly regulating the conformation and activity of
metabolic enzymes. Phosphorylation of glycogen phosphorylase and glycogen synthase
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exemplifies a typical mechanism that PTM directly regulate catalytic activity of metabolic
enzymes (Browner and Fletterick, 1992; Johnson, 1992; Soderling et al., 1979). Very few
examples are known whether a metabolic enzyme is regulated by a PTM that affects the
proteins stability and links to nutrient condition.
Acetylation has been identified as an evolutionarily conserved modification in metabolic
enzymes and has emerged to play major roles in metabolic regulation (Wang et al., 2010;
Zhao et al., 2010). In bacteria, acetylation has been found not only to control activities of
key metabolic enzymes such as acetyl CoA synthetase and glyceraldehyde dehydrogenase
but also to play critical roles in coordinating activities of metabolic pathways according to
different carbon source availability (Starai et al., 2002; Wang et al., 2010). In eukaryotic
cells, a number of recent studies have rapidly revealed that acetylation regulates key
metabolic enzymes in urea and TCA cycles, gluconeogenesis, fatty acids metabolism and
reactive oxygen species scavenge system (Hirschey et al.; Kim et al.; Nakagawa et al., 2009;
Qiu et al.; Someya et al.; Zhao et al., 2010). The consequence of acetylation on these
enzymes is that they directly affect catalytic activity of these enzymes via different
mechanisms (Lin et al., 2009; Someya et al.; Wang et al., 2010; Zhao et al., 2010).
PEPCK1 is a cataplerotic enzyme that plays important functions in gluconeogenesis,
glyceroneogenesis, serine synthesis and amino acid metabolism (Hanson and Patel, 1994;
Nye et al., 2008; Tannen, 1978). It catalyzes the first committed and rate limiting step of
gluconeogenesis, which plays critical functions, mainly in liver and to a lesser extent in
kidney and small intestine, to maintain glucose homeostasis (Chakravarty et al., 2005). It is
well established that changes in the rate of transcription of PEPCK1, an event regulated by
transcription factors such as PGC-1α and HNF-1 in response to hormones and diets
(Granner and O'Brien, 1992; Hanson and Reshef, 1997; Yoon et al., 2001), is of critical
importance in maintaining the overall PEPCK1 activity. Since elevated gluconeogenesis is
an important marker in the evaluation of type II diabetes (Granner and O'Brien, 1992),
mechanisms that are involved in PEPCK1 regulation have been extensively studied.
Yeast PEPCK1 has been reported to be acetylated at Lys19 and Lys514 and acetylation
inactivates its catalytic activity (Lin et al., 2009). Human PEPCK1 was identified to be
acetylated at Lys70, Lys71 and Lys594 by cell wide protein acetylation profiling (Zhao et al.,
2010), and acetylation of PEPCK1 leads to decreased protein stability (Zhao et al., 2010).
This study is directed toward to understand the underlining mechanism of acetylation-
induced PEPCK1 reduction.
RESULTS
Acetylation promotes PEPCK1 degradation via ubiquitin-proteosome pathway
In order to elucidate the nature of acetylation in human PEPCK1 stability regulation,
HEK293, HepG2, Chang’s and HEK293T cells were each treated with a deacetylase
inhibitor cocktail that contains nicotinamide (NAM) and trichostatin A (TSA), a chemical
combination that supposedly inhibits all four classes of known deacetylases (Xu et al.,
2007). Confirming our previous finding (Zhao et al., 2010), steady state levels of
endogenous PEPCK1 were decreased 50–70% by inhibition of deacetylases (Figures 1A,
1B). When MG132 was included in cell culture medium to inhibit proteosomal degradation,
steady state PEPCK1 levels increased by more than 60% in HEK293T cells and, notably,
this treatment cancelled the destabilization effect of NAM+TSA treatment on PEPCK1
(Figure 1B). These results suggested that acetylation-promoted decrease of PEPCK1 is
likely mediated by the ubiquitin-proteosome pathway. Consistent with this notion, when
Flag-tagged PEPCK1 was co-expressed with HA-tagged ubiquitin, active PEPCK1
ubiquitinylation was detected and inhibition of deacetylases significantly increased PEPCK1
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ubiquitinylation (Figures 1C, 1D). Moreover, inhibition of deacetylases further increased
PEPCK1 ubiquitination in the presence of MG132. The promotional role of inhibition of
deacetylases on PEPCK1 ubiquitination, however, was not observed when all three putative
acetylation lysine residues of PEPCK1 were changed to non-acetylable arginine residues
(PEPCK13K/R). When PEPCK13K/R was expressed in HEK293T cells, purified
PEPCK13K/R protein had a low basal level of ubiquitination, and more importantly, its
ubiquitination level did not respond to inhibition of deacetylases (Figure 1D), indicating that
PEPCK1 ubiquitination depends on acetylation.
PEPCK1 interacts with proteins involved in proteosome degradation
To elucidate the regulatory mechanism of PEPCK1 degradation, we established a HEK293T
derivative cell line that stably expressed PEPCK1 with both Flag and streptavidin-binding
peptide (SBP) tagged to the N-terminus. Tandem affinity purification with Flag beads and
streptavidin- agarose beads followed by mass spectrometry analysis allowed us to identify
proteins that specifically interact with PEPCK1. Among the consistently identified proteins
were BAT3, UBR5, ubiquitin, and various proteosome associated proteins (Figure 1E, Table
S1). That PEPCK1 interacts with many proteins associated with the ubiquitin-proteosome
pathway further strengthens the case for PEPCK1 degradation through ubiquitin-proteosome
pathway. Interestingly, BAT3 is a known enhancer of the p300 acetyltransferase as well as a
co-chaperone that regulates protein degradation via the ubiquitin-proteosome pathway
(Sasaki et al., 2007; Takayama and Reed, 2001); UBR5 (ubiquitin protein ligase E3
component n-recognin 5, also known as EDD1, DD5 and HYD) is a HECT domain E3
ubiquitin ligase (Callaghan et al., 1998; Honda et al., 2002). These observations indicate that
BAT3 and p300 may be involved in PEPCK1 acetylation, while UBR5 could serve as a
potential E3 ubiquitin ligase to regulate PEPCK1 stability.
UBR5 is involved in glucose dependent PEPCK1 degradation
We examined the role of UBR5 in regulation of PEPCK1 protein stability. PEPCK1 had a
rather short half-life of approximately 30 minutes under high glucose conditions. However,
PEPCK1 protein stability was dramatically increased when UBR5 was knocked down by
siRNA (Figure 2A, Figure S1A). Consistently, UBR5 knockdown resulted in a significant
increase in steady state level of PEPCK1 (Figure 2B). These results suggest that UBR5 plays
a role in PEPCK1 degradation.
As the key enzyme in balancing cellular glucose homeostasis, PEPCK1 activity is inversely
regulated by glucose concentrations [(Panin et al., 1979; Scott et al., 1998), Figure 2C].
However, in cells with UBR5 knocked down, high glucose failed to reduce PEPCK1 levels
(Figure 2C, right panel). Furthermore, inhibition of deacetylases decreased the steady state
PEPCK1 levels (Figure S1B, upper panel); whereas UBR5 knock down prevented the
reduction of endogenous PEPCK1 by inhibition of deacetylases (Figure S1B, lower panel).
Collectively, these data demonstrate that UBR5 is required for PEPCK1 regulation by
glucose and it promotes PEPCK1 degradation possibly by serving as the E3 ubiquitin ligase
for PEPCK1.
UBR5 interacts with and degrades PEPCK1 through its C-terminal domain
In an attempt to analyze UBR5-PEPCK1 interaction, we found endogenous UBR5 co-
precipitated with overexpressed PEPCK1 (Figure S1C), conversely, endogenous PEPCK1
co-precipitated with overexpressed UBR5 (Figure S1D). Moreover, the interaction between
endogenous PEPCK1 and endogenous UBR5 was enhanced by deacetylase inhibitor
treatment (Figure 2D), suggesting acetylation promotes PEPCK1-UBR5 interaction. UBR5
is a large protein containing 2,799 amino acid residues. To map the specific domain of
UBR5 that is responsible for PEPCK1-UBR5 interaction, we generated N-terminal zinc
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finger containing fragment (1-1245, UBR5-N), central fragment (1246-2375, UBR5-M), and
C-terminal HECT domain containing fragment (2375-2799, UBR5-C) of UBR5 (Figure
S1E) and tested their interaction with PEPCK1 and found that PEPCK interacted with
UBR5-C but not with either UBR5-N or UBR5-M (Figure S1F). Since UBR5-C contains
catalytic HECT domain, it could act as an E3 ligase towards PEPCK1 and thus promote
PEPCK1 degradation. We tested this possibility by ectopically expressing UBR5-C and a
catalytic inactive mutant of UBR5-C (UBR5-C C2768A, referred thereafter as UBR5-C-C/
A) that still keep the ability to bind to PEPCK1 (see Figure 2G) and determined steady state
endogenous PEPCK1 protein levels. Only in cells overexpressing UBR5-C the endogenous
PEPCK1 level was markedly decreased and ectopically expression of UBR5-C-C/A could
not reduce PEPCK1 protein level (Figure 2E). Together, these results indicate that the E3
ligase activity of UBR5-C is required for UBR5-C to decrease PEPCK1 protein level.
Acetylation of PEPCK1 promotes UBR5-PEPCK1 interaction
A key mechanism in regulation of protein ubiquitination is the interaction between a target
protein and its specific E3 ligase (Skowyra et al., 1997). We investigated the role of
acetylation in UBR5 dependent PEPCK1 degradation. Since inhibition of deacetylases
enhances the interaction between PEPCK1 and UBR5 in vivo (Figure 2D), we investigated
the role of PEPCK1 acetylation in PEPCK1-UBR5 interaction by comparing the binding of
PEPCK1 and the non-acetylable PEPCK1 mutants with UBR5-C in response to inhibition of
deacetylases. The interaction between Flag-PEPCK1 and Myc-UBR5-C was readily
detectable and was enhanced by more than two-fold upon deacetylase inhibitor treatment;
the interaction between PEPCK13K/R and UBR5-C was barely detectable and was not
responsive to inhibition of deacetylases (Figure 2F). Moreover, acetylation mimetic
PEPCK13K/Q mutant had stronger interaction with UBR5-C than wild type PEPCK1 (Figure
S1G). These results support the notion that acetylation of PEPCK1 facilitates binding to
UBR5. To further confirm this notion, we tested whether the UBR5-associated PEPCK1 is
highly acetylated compared with the free PEPCK1. UBR5-C-C/A and PEPCK1 was co-
expressed in HEK293T cells. PEPCK1 was co-immunoprecipitated by UBR5-C-C/A and the
relative acetylation level of the co-precipitated PEPCK1 was compared with the free
PEPCK1 that was not co-precipitated by UBR5-C-C/A. We observed that PEPCK1 protein
co-purified with UBR5-C-C/A had a much higher relative acetylation level than PEPCK1
protein purified from lysates post UBR5 immunoprecipitation (Figure 2G). This result
clearly demonstrates that acetylated PEPCK1 is preferentially associated with UBR5 and
suggests an underlining molecular mechanism of PEPCK1 acetylation in promoting its
degradation by increasing interaction with the UBR5.
The physiological correlation between PEPCK1 acetylation and its UBR5 binding was
investigated by determining PEPCK1-UBR5 binding under increasing glucose
concentrations. High glucose increases PEPCK1, but not PEPCK13K/R acetylation [(Zhao et
al., 2010), Figure S1H]. When UBR5-C and PEPCK1 was coexpressed in HEK293T cells
maintained under different glucose concentrations and in the presence of MG132, we
observed that high glucose promoted UBR5-C-PEPCK1 interaction in a dosage dependent
manner (Figure 2H). Furthermore, the amount of UBR5-associated PEPCK1 in cells
cultured in 25 mM glucose increased approximately one-fold compared with cells cultured
in glucose-free medium (Figure 2I). In contrast, the non-acetylable PEPCK13K/R mutant
displayed little interaction with UBR5, and more importantly, glucose could not increase the
interaction between UBR5 and PEPCK13K/R (Figure S1I). These results show that the
UBR5-PEPCK1 interaction is under control by acetylation, which is regulated by glucose
concentrations.
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P300 acetylates and destabilizes PEPCK1
Our affinity purification identified BAT3, a known enhancer of P300 (Mantelingu et al.,
2007), as an interacting protein of PEPCK1 led us to investigate a possible involvement of
P300 in PEPCK1 acetylation. Notably, the sequence flanking acetylated Lys70 and Lys71 of
PEPCK1 matches the consensus sequence of P300 substrates [(Liu et al., 2008), Figure
S2A]. To experimentally demonstrate PEPCK1 is a substrate of P300, P300 and other
acetyltransferases, including PCAF, CBP and GCN5, were co-transfected with PEPCK1 and
the acetylation status of PEPCK1 was determined. Our data showed that only P300, but not
the other acetyltransferases, increased PEPCK1 acetylation (Figure 3A). Moreover, co-
expression of the catalytic inactive P300S1396R/Y1397R mutant did not increase PEPCK1
acetylation (Figure 3B), indicating that P300 acetyltransferase activity is required for
PEPCK1 acetylation. Furthermore, co-expression of P300 increased acetylation levels of
wild type PEPCK1, but not PEPCK13K/R, indicating that P300 acts on these lysine residues
of PEPCK1 (Figure S2B). Contrary to overexpressing P300 increased PEPCK1 acetylation
(Figure 3A), knockdown of P300 significantly decreased PEPCK1 acetylation level (Figure
3C). In addition, PEPCK1 could be co-immunoprecipitated by P300 when both were co-
expressed in 293T cells (Figure 3D) and P300-PEPCK1 interaction increased with glucose
concentration in a dose dependent manner (Figure 3E). These results support the notion that
P300 is an acetyltransferase for PEPCK1. Consistent with this notion is a finding that
although P300 mainly localized in nucleus, when PEPCK1 was overexpressed in Chang’s
Liver cells, increased amount of P300 was detected localized in cytoplasm, the compartment
in which PEPCK1 is located (Figure S2C).
The effect of P300 on PEPCK1 stability was also studied. Steady state PEPCK1 levels were
determined when P300 and other related acetyltransferases were each ectopically expressed
in HEK293T cells. Expression of P300 decreased the steady state PEPCK1 protein level by
70%, while expression of other acetyltransferases caused no discernable change of PEPCK1
protein levels (Figure 3F), suggesting that increased P300 activity in cells destabilized
PEPCK1. The destabilizing ability of P300 on PEPCK1 was again found to be dependent on
the catalytic activity of P300 because ectopically expressing of catalytic inactive
P300S1396R/Y1397R mutant in HEK293T cells did not cause any change in steady state
PEPCK1 protein level (Figure 3G), consistent with the finding that knockdown of P300 in
Chang’s cells by siRNA reduced endogenous PEPCK1 decreasing rate with increased
glucose concentrations (Figures 3H, S2D), supporting P300 as the acetyltransferase of
PEPCK1.
BAT3 enhances PEPCK1 acetylation and destabilizes PEPCK1
BAT3 enhances P53 acetylation by forming a complex with P300 and recruiting P53 to
P300 (Mantelingu et al., 2007; Sasaki et al., 2007). To test whether BAT3 enhances
PEPCK1 acetylation, we first tested interactions among P300, BAT3 and PEPCK1. We
found that PEPCK1 interacted with both BAT3 and P300 individually (Figures 4A, 4B, 4C,
3D). These results indicate that BAT3, and P300 can both exist in the PEPCK1 protein
complex, suggesting the possibility that BAT3 could be an enhancer of PEPCK1 acetylation.
Furthermore, when either BAT3 or P300 was co-expressed with PEPCK1, there was an
increase in PEPCK1 acetylation level (Figure 4D, lanes 1, 2, 4); moreover, when both BAT3
and P300 were co-expressed, PEPCK1 acetylation level was further increased by more than
2-fold (Figure 4D, lanes 1, 3), indicating a synergistic effect of BAT3 and P300 to promote
PEPCK1 acetylation. Consistent with the acetylation results, expression of P300 in
HEK293T cells caused a significant decrease in endogenous PEPCK1 level and co-
expression of BAT3 further decreased the steady state PEPCK1 protein level (Figure 4E).
These results collectively support a model that BAT3 enhances the ability of P300 to
acetylate PEPCK1 and therefore, contributes to PEPCK1 protein level regulation.
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Next, the deacetylase responsible for PEPCK1 regulation was investigated. Taking
advantage that TSA and NAM inhibit certain type of deacetylases, we first measured
PEPCK1 acetylation levels in cells treated with TSA, a class I, II and IV deacetylases
inhibitor, and NAM, an NAD+ dependent class III deacetylases inhibitor (Xu et al., 2007).
NAM treatment led to more than a 300% increase in PEPCK1 acetylation while TSA
treatment caused negligible acetylation level change (Figure S3A), suggesting that PEPCK1
is deacetylated by a class III enzyme. There are 7 known class III deacetylases in
mammalian cells, namely Sirt1-7 among which Sirt1 and Sirt2 are the two major cytosolic
members. Since PEPCK1 is a cytosolic protein, we thus examined the possibility of Sirt1
and Sirt2 being the deacetylase for PEPCK1. When PEPCK1 was co-expressed with Sirt1
and Sirt2 in 293T cells, Sirt2 interacted strongly with PEPCK1 while Sirt1 showed no
interaction (Figure S3B), suggesting a possible role of Sirt2 in PEPCK1 deacetylation.
Moreover, co-expressing Sirt2, but not Sirt1, with PEPCK1 in HEK293T cells caused an
approximate 70% decrease of PEPCK1 acetylation level (Figure 5A), supporting a role of
Sirt2 in PEPCK1 deacetylation. Moreover, co-expressing Sirt2 with wild type PEPCK1, but
not with PEPCK13K/R, decreased PEPCK1 acetylation level by 40% (Figure S3C).
Furthermore, when wild type Sirt2, but not its catalytic inactive S368D and H187Y mutants
(North et al., 2003; North and Verdin, 2007), was coexpressed with PEPCK1, a 65%
decrease of PEPCK1 acetylation level was observed (Figure 5B), connecting PEPCK1
deacetylation directly to Sirt2 catalytic activity. Consistently, a 50% increase in steady state
endogenous PEPCK1 level was observed by overexpression of wild type Sirt2, but not its
catalytic inactive S368D and H187Y in HEK293T cells (Figure S3D). Together, protein-
protein interaction and Sirt2 overexpression results all support that Sirt2 is the deacetylase of
PEPCK1. This notion was also tested under Sirt2 knock down conditions. PEPCK1
acetylation level increased by more than 100% when PEPCK1 was expressed in HEK293T
cells with endogenous Sirt2 is knocked down by siRNA (Figure 5C); moreover, knock down
of Sirt2 by siRNA caused more than a 70% decrease in steady state endogenous PEPCK1
level (Figure 5D), consistent with our model that acetylation destabilizes PEPCK1 (Figure
1A). Taken together, all results support a conclusion that Sirt2 is the major deacetylase that
acts on PEPCK1.
Sirt2 decreases PEPCK1 ubiquitinylation
Since acetylation enhances the interaction between UBR5 and PEPCK1 (Figures 2D, 2F), a
predicted consequence of overexpression of Sirt2 would be that Sirt2 will decrease the
association between PEPCK1 and UBR5 by decreasing acetylation of PEPCK1 and
subsequently stabilize PEPCK1. Indeed, overexpressing Sirt2 in 293T cells decreased
interaction between PEPCK1 and UBR5-C-C/A (Figure 5E). That Sirt2 decreases UBR5-
PEPCK1 interaction by deacetylating PEPCK1 is further evidenced by the result that
expression of Sirt2 significantly decreased PEPCK1 ubiquitination (Figure 5F) and
moreover, by an observation that overexpression of the catalytic inactive Sirt2 S368D and
H187Y mutants did not decrease PEPCK1 ubiquitinylation (Figure 5F). Contrary to
increased Sirt2 activity by overexpression, we also tested the consequence of decreasing
Sirt2 activity. We treated cells with Sirtinol, a chemical that inactivates Sirt2 catalytic
activity specifically (Outeiro et al., 2007), and observed that Sirtinol treatment caused a
dramatic increase in ubiquitinylation of PEPCK1, a result that is opposite to Sirt2
overexpression, in a dose dependent manner (Figure 5G). When steady state endogenous
PEPCK1 levels of Sirtinol treated cells were determined, we found that PEPCK1 level
decreased with increased Sirtinol concentration (Figure 5H), consistent to an increased
ubiquitinylation level by Sirtinol treatment. Notably, the transcription level of PEPCK1 was
not affected by Sirtinol treatment (Figure 5H), excluding the possibility that altered PEPCK1
level by Sirtinol treatment was a result of altered PEPCK1 transcription. Collectively, the
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above data show that Sirt2 decreases PEPCK1 ubiquitinylation and increases protein
stability.
PEPCK1 acetylation and ubiquitinylation are regulated by nutrients
Being the key enzyme that controls gluconeogenesis, PEPCK1 activity is tightly regulated
by cellular glucose levels. Consistent with a previous report that p300 transcription was up-
regulated by glucose (Chen et al., 2010), we found glucose mildly activates transcription of
P300 (Figure 6A). In contrast, Sirt2 mRNA level was decreased with elevated glucose
concentrations (Figure 6B). Consistently, Sirt2 mRNA levels in starved mice hepatocytes
increased about 50% (Figure 6C). These results support a notion that high glucose increases
PEPCK1 acetylation through combined effects of increasing P300 transcription and
decreasing Sirt2 transcription. We next tested whether PEPCK1 ubiquitination was regulated
by glucose, which is known to induce PEPCK1 acetylation. A progressive increase of
PEPCK1 ubiquitination was observed with increasing glucose concentrations (Figure 6D).
This glucose-induced PEPCK1 ubiquitination is through increased PEPCK1 acetylation
because non-acetylation mutant PEPCK3K/R ubiquitination is not responsive to elevated
glucose concentrations (Figure S4A). Notably, when 293T cells were maintained in glucose
free medium with different concentrations of amino acids, PEPCK1 ubiquitination level
decreased with increasing amino acid concentrations (Figure S4B), consistent with the
previous finding that amino acids decrease PEPCK1 acetylation (Zhao et al., 2010) and the
notion that stability of PEPCK1 is regulated by its acetylation. Together, these results
suggest that acetylation of PEPCK1 is regulated by different nutrients and controls PEPCK1
degradation according to the requirement of physiological needs.
Changing acetylation and ubiquitination affects gluconeogenesis
Lastly, the biological relevance of PEPCK1 acetylation and degradation in gluconeogenesis
was investigated. When UBR5-C was overexpressed in 293T cells maintained in glucose
free medium, it caused an approximate 50% decrease in cellular PEPCK1 level and a 35%
decrease in glucose production (Figure 6E), suggesting that gluconeogenesis can be
controlled by manipulating the PEPCK1 E3 ligase activity. Unexpectedly, when the
catalytically inactive UBR5-C-C/A was overexpressed in 293T cells, we observed an
increase of approximately 40% in cellular PEPCK1 protein level and a mild increase in
glucose production (Figure 6E). This is likely through a dominant negative effect of UBR5-
C-C/A, whereby a high concentration of UBR5-C-C/A competes with endogenous UBR5
for binding to PEPCK1, further confirming the involvement of UBR5 in PEPCK1
degradation and suggesting that inhibition of UBR5 activity could lead to elevated glucose
production. Indeed, when cellular UBR5 mRNA levels were each knocked down to about
20% of its original level in both Chang’s and 293T cells, there was a roughly 200% increase
of cellular PEPCK1 protein levels and 60% increase in glucose production (Figures 6F,
S4C). We then confirmed that PEPCK1 protein levels and gluconeogenesis rate could be
modulated by altering PEPCK1 acetylation. Knocking down of P300, a manipulation that
would decrease PEPCK1 acetylation, caused about 200% and 50% cellular PEPCK1
increase in 293T cells and Chang’s cells, respectively; and resulted in a 90% and 50%
increase in glucose production in these two cells, respectively (Figures 6G, S4D). In
contrast, knocking down Sirt2, which increase PEPCK1 acetylation level, caused 80%
decrease in PEPCK1 level and 35% decrease in glucose production in HEK293T cells
(Figure 6H). Consistently, inhibition of Sirt2 by Sirtinol decreases steady state PEPCK1
level by 60% and decreases the glucose production by 40% in Chang’s liver cells (Figure
S4E).
Conversely, overexpressing Sirt2 in Chang’s liver cells caused a 50% increase in steady
state PEPCK1 level and 43% increase in glucose production (Figure S4F). Finally, we
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investigated whether PEPCK1 level and gluconeogenic rate can be regulated by altering
Sirt2 level in mice. Tail vein injection of adenovirus packed with Sirt2 shRNA in mice
effectively reduced Sirt2 levels of mice liver by approximately 45% (Figure S4G) and
decreased PEPCK1 level by about 70% (Figures 6I upper panel and S4H). Sirt2 knock down
didn’t cause Pepck1 mRNA level change (Figure S4I), excluding the possibility that
decreased liver Pepck1 levels were due to altered transcription. Supporting a decrease in
liver Pepck1 levels by Sirt2 knockdown, average blood glucose levels of mice with Sirt2
knocked down decreased about 35% (Figures 6I lower panel and S4J). Together, these
results showed that modulation of PEPCK1 acetylation or ubiquitinylation, hence protein
levels, may serve an important mechanism to regulate the rate of cellular gluconeogenesis.
DISCUSSION
Virtually all intermediate metabolic enzymes are acetylated and many examples have shown
an important role of acetylation in metabolic enzyme activity/function regulation. In this
study, we have uncovered a biochemical mechanism presenting how acetylation controls
metabolic enzyme stability and providing a physiological role of acetylation in regulation of
gluconeogenesis. We propose that acetylation plays a critical role in coordinating the level
of PEPCK1, hence the gluconeogenesis rate, with the availability of nutrients, such as
glucose and amino acids. When glucose is sufficient, gluconeogenesis should be suppressed.
This is achieved in part by glucose-induced degradation of PEPCK1. High glucose
concentration increases PEPCK1 acetylation, which promotes its interaction with the UBR5
E3 ubiquitin ligase. As a result, the acetylated PEPCK1 is ubiquitinylated and subsequently
degraded by proteasomes. Therefore, gluconeogenesis is suppressed. In contrast, when
glucose level is low, PEPCK1 is stabilized, hence gluconeogenesis is enhanced. Our data
show that both P300 and Sirt2 are major enzymes responsible for PEPCK1 acetylation and
deacetylation, respectively. Therefore, PEPCK1 stability is controlled by a regulatory
network including P300, Sirt2, and UBR5 in response to glucose status.
Although our study provides insights into the cellular regulation of gluconeogenesis in
response to nutrient availability, it also raises questions regarding how cells sense glucose
levels to regulate PEPCK1 acetylation and what the molecular basis of acetylation is in
promoting the interaction between PEPCK1 and UBR5. Sirt2 uses NAD+ as a co-factor and
has been implicated in metabolism regulation and possibly cellular energy response. The
NAD+/NADH ratio is an indicator for cellular energy status. It is possible that Sirt2 may
sense cellular NAD+ levels, to influence PEPCK1 and thus gluconeogenesis, which requires
energy and reducing power to produce glucose. Acetyl-coA, an essential substrate for
protein acetyltransferases, is a key metabolic intermediate. Therefore, it is not surprising that
nature may use acetyl-CoA and acetylation to modulate metabolism because the level of
acetyl-CoA may serve as an indicator of cellular metabolic status.
The regulation of gluconeogenesis is unique in two aspects. First, this process consumes
much energy; a quick shut down of this process when it is not needed is required. On the
other hand, when physiological glucose level is low, a quick turn on of gluconeogenesis is
required to supply glucose for the brain or other important organs. Both aspects need prompt
change of cellular PEPCK1 activity since it is the rate limiting enzyme in gluconeogenesis.
Compared to a translational control on PEPCK1 that usually takes hours to happen,
proteosomal degradation can occur within minutes and thus could serve as a better way to
rapidly respond to physiological glucose variation. Future study is of interest to demonstrate
if acetylation-induced protein degradation is a general mechanism in regulation of metabolic
enzymes.
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Full-length PEPCK1, P300 and Sirt2 were cloned to a Flag-, Myc- or HA-tagged destination
vectors according to different needs. Point mutations for PEPCK1, UBR5, P300, and Sirt2
were generated by site-directed mutagenesis. Mapping of UBR5 was made by cloning PCR
fragments into Flag- or Myc-tagged vectors.
Antibodies
Rabbit anti-pan-acetyllysine antibodies were produced as previously described. Antibodies
to PEPCK1 (Santa Cruz), Flag (Sigma), Myc (Santa Cruz), HA (Santa Cruz), P300
(NeoMarkers), and UBR5 (Bethyl Laboratories) were purchased commercially.
Cell Culture and Treatment
All experiments were carried out in HEK293T cells unless specified. Cells were culture in
Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% newborn bovine
serum. The deacetylase inhibitor TSA was added 18 hours before harvest at the final
concentration of 10uM, while 5mM NAM was added into medium 4–6 hours before harvest.
Glucose or amino acid only medium was prepared with DMEM base and supplemented with
glucose or amino acids of different concentration as indicated. For ubiquitination assays, the
protease inhibitor MG132 was added 3 hours before harvest.
Tandem Affinity Purification
293T cells were transfected with pMCB-SBPFlag-PEPCK containing a puromycin-
resistance marker. The PEPCK-positive stable cells were lysed on ice in 0.1%NP40 buffer
(20mM Tris-HCl, pH8.0, 150mM NaCl) containing a protease inhibitor cocktail for 30 min.
After removal of insoluble cell debris by centrifugation, cell lysates were incubated with
streptavidin-Sepharose beads (GE Healthcare) for 3 hours at 4°C. The precipitates were
washed 3 times with NP-40 buffer and 3 times with 50mM NH4CO3. On-beads tryptic
digestion was performed at 37°C overnight. The peptides in supernatant were dried in a
speed vacuum (Eppendorff) and re-dissolved in NH4CO3 buffer containing 0.1% formic
acid and 5% acetonitrile before being subjected to Mass Spectrometry.
Cell transfections, immunoprecipitation and immunoblotting
Plasmid transfections were carried out by the calcium phosphate method. For
immunopreciptation, cells were lysed with 0.1%NP-40 buffer as described above. Cell
lysates were incubated with Flag beads (Sigma) for 3 hours at 4°C The binding complexes
were washed with NP-40 buffer and then subjected to SDS-PAGE. For western blotting of
tagged proteins, conventional procedures were employed. For acetylation Western Blotting,
50 mM Tris (pH 7.5) with 10% (V/V) Tween-20 and 1% peptone (AMRESCO) was used
for blocking and 50 mM Tris (pH 7.5) with 0.1% peptone was used to prepare primary and
secondary antibodies.
In vivo ubiquitination assay
36 hours after transfection, cells were lysed in 1% SDS buffer (Tris pH7.5, 0.5mM EDTA,
1mM DTT) and boiled for 10 minutes. For immunoprecipitation, the lysates were diluted
10-fold in Tris-HCl buffer. Analyses of ubiquitination were performed by anti-HA blotting.
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Control and siSirt2 adenovirus were purchased from Vector Biolabs. P300, UBR5 and Sirt2
knocking down were carried out by using synthetic siRNA oligonucleotides synthesized
from Genepharma, Shanghai. For each target gene, we employed two effective target
sequences to exclude off-target effects. Transfections were performed by using
Lipofectamine 2000 (Invitrogen). The knock down efficiency was verified by q-RT-PCR.








293T and Chang’s cells expressing siRNA or plasmids were cultured in DMEM. The
medium was replaced with 1 ml of DMEM base supplemented with 2 mM sodium pyruvate
and 20 mM sodium lactate. After 3 hr incubation, medium was collected and the glucose
concentration was measured with a colorimetric glucose assay kit (GAGO20; Sigma-
Aldrich). The readings were normalized to the total protein content determined from the
whole-cell extracts.
Nuclear / Cytoplasma Isolation
Cells were lysed in harvest buffer (10mM HEPES, 50mM NaCl, 0.5M Sucrose, 0.1mM
EDTA, 0.5% Triton100, 1mM DTT, pH 7.9). The lysates were centrifuged at 1000rpm. The
supernatant (cytoplasmic extract) were collected. The pellets (nuclear extracts) were washed
3 times and then boiled in 1% SDS for western analysis.
Animal Experiments
All animal experiments conformed to protocols approved by animal care and use
committees at Fudan University. Experiments were performed in 6- to 8-week-old male
BALB/c mice, purchased from Shanghai Medical School of Fudan University. Animals
were housed in a humidity- and temperature-controlled room with a 12:12 h dark/light cycle.
Adenovirus infections were performed by tail vein injection with 0.5×108 infectious
particles per mouse. At Day 6, mice were fasted for 6 hours before sacrifice. Livers were
removed and whole-cell homogenates were made with NP40 buffer and used for western
blot analysis. Liver mRNA was isolated using Trizol reagent (Invitrogen) and used for
quantitative PCR. Blood was collected from tail vein for glucose detection (Roche).
Statistic Method
Statistics were performed with a two-tailed unpaired Student's t-test.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Glucose destabilizes PEPCK1 by inducing its acetylation
P300 and SIRT2 regulates PEPCK1 acetylation
UBR5 ubiquitinates the acetylated PEPCK1
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Figure 1. Acetylation promotes ubiquitin-proteosome degradation of PEPCK1
(A) Acetylation promotes cellular PEPCK1 degradation. Endogenous PEPCK1 levels of
HEK293, HepG2 and Chang’s liver cells were determined under both with and without
deacetylase inhibitor treatment. (B) Acetylation-promoted PEPCK1 degradation is inhibited
by proteosome inhibitor. 293T cells were treated or not treated by TSA and NAM in the
absence or presence of MG132. Endogenous PEPCK1 was probed by anti-PEPCK1
antibody. (C) Deacetylase inhibitors increase the ubiquitination of PEPCK1. Ubiquitination
levels of affinity purified Flag-PEPCK1 proteins expressed under treated or not treated by
NAM+TSA in the absence or presence of MG132 were detected. (D) Deacetylase inhibitors
do not affect PEPCK13K/R acetylation level and protein stability. The acetylation levels and
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ubiquitination levels of affinity purified PEPCK13K/R protein expressed under with or
without NAM+TSA treatment were determined. (E) Identification of PEPCK1 interacting
proteins. PEPCK1 interacting proteins involved in acetylation and ubiquitination are shown.
See also Table S1.
Jiang et al. Page 15













Figure 2. UBR5 is an E3 ligase of PEPCK1
(A) UBR5 knockdown stabilizes PEPCK1. PEPCK1 levels of 293T cells with or without
UBR5 knocked down were determined at different time points after CHX was added. Shown
are representative western blot results of three replicates. Average quantified relative protein
abundance from all three repeats is shown with SD. (B) UBR5 knockdown increases steady
state PEPCK1 level. UBR5 in 293T cells was knocked down by siRNA and steady state
PEPCK1 level was determined. Results of two different siRNA oligos are shown. (C) UBR5
knockdown abolishes glucose induced PEPCK destabilization. Steady state PEPCK1 levels
of HEK293T cells and HEK293T cells with UBR5 knocked down were determined under
different glucose concentrations. (D) Inhibition of deacetylases promotes endogenous
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PEPCK1-UBR5 interaction. Endogenous PEPCK1 levels co-precipitated with endogenous
UBR5 under with and without MG132 treatment were detected. (E) Overexpressed UBR5-C
decreases steady state PEPCK1 level. Steady state PEPCK1 levels of 293T cells were
measured when UBR5 domains were overexpressed. (F) Deacetylase inhibitors affect
PEPCK1-UBR5 interaction. PEPCK1-UBR5-C and PEPCK13K/R–UBR5-C interactions
were determined with or without TSA and NAM treatment. (G) UBR5 binds to acetylated
PEPCK1. UBR5-C-C/A and PEPCK1 were co-expressed in 293T cells. Acetylation levels of
PEPCK1 associated with UBR5-C-C/A. (H) PEPCK1-UBR5 interaction is enhanced by high
glucose. Myc-PEPCK1 and Flag-UBR5-C were co-expressed in 293T cells maintained at
different glucose concentrations and PEPCK-UBR5-C interaction was by IP-western. (I)
Glucose increase PEPCK1-UBR5 interaction. Endogenous UBR5 proteins in Chang’s cells
cultured in 25mM glucose and glucose free media were precipitated and PEPCK-UBR5-C
interaction was determined. See also Figure S1.
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Figure 3. P300 acetylates PEPCK1 and promotes its degradation
(A) P300 acetylates PEPCK1. Flag-PEPCK1 was co-expressed with different
acetyltransferases and purified by Flag beads. Acetylation levels of purified Flag-PEPCK1
proteins were determined. (B) Catalytic activity of P300 is required to acetylate PEPCK1.
Acetylation levels of PEPCK1 co-expressed with P300 or its catalytic mutant were
determined. (C) P300 knockdown decreases PEPCK1 acetylation level. Acetylation levels
of Flag-PEPCK1 expressed and purified from 293T cells with or without P300 knocked
down by siRNA were detected. (D) P300 interacts with PEPCK1. Interaction between co-
expressed Flag-P300 and Myc-PEPCK1 was detected. (E) P300-PEPCK1 interaction is
Jiang et al. Page 18













enhanced by glucose. Interaction between Flag-P300 and Myc-PEPCK1 co-expressed under
different concentrations of glucose was determined. (F) P300 overexpression decreases
steady state PEPCK1 level. Steady state PEPCK1 levels of 293T cells overexpressing
different acetyltransferases were determined. (G) Catalytic activity of P300 is required for
decreasing steady state PEPCK1 level. PEPCK1 levels of 293T cells and 293T cells
expressing P300 and P300S1396R/Y1397R were determined. (H) P300 is required for PEPCK1
degradation. PEPCK1 degradation rates of Chang’s cells with and without P300 knocked
down were measured under both low (0mM) and high (25mM) glucose concentrations. See
also Figure S2.
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Figure 4. BAT3 enhances PEPCK1 acetylation and promotes its degradation
(A,B) BAT3 interacts with PEPCK1. Interactions between BAT3 and PEPCK1 were
determined when proteins were co-expressed with each other in HEK293T cells. (C) BAT3
interacts with P300. Interactions between co-expressed BAT3 and P300 were analyzed. (D)
BAT3 enhances PEPCK1 acetylation. Acetylation levels of PEPCK1 expressed and purified
from 293T cells and 293T cells co-expressing P300 and P300 plus BAT3 were determined.
(E) BAT3 overexpression decreases PEPCK1 level. Steady state PEPCK1 levels of 293T
cells and 293T cells overexpressing P300 and P300 plus BAT3 were determined.
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Figure 5. Sirt2 deacetylates and stabilizes PEPCK1
(A) Sirt2 deacetylates PEPCK1. Acetylation levels of PEPCK1 expressed and purified from
293T cells and 293T cells co-expressing Sirt1 and Sirt2 were detected. (B) Sirt2 deacetylates
PEPCK1. Acetylation levels of Flag-PEPCK1 expressed and IP purified from HEK293T
cells and HEK293T cells co-expressing Sirt2, Sirt2S368D and Sirt2H187Y, respectively, were
determined. (C) Sirt2 knockdown increases PEPCK1 acetylation level. Acetylation levels of
PEPCK1 expressed from HEK293T cells and HEK293T cells with Sirt2 knocked down
were probed by panacetyllysine antibody. Sirt2 knockdown efficiency was monitored by
realtime PCR. (D) Sirt2 knockdown decreases PEPCK1 protein level. Endogenous PEPCK1
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levels of HEK293T cells and HEK293T cells with Sirt2 knocked down were determined by
anti-PEPCK antibody. (E) Overexpression Sirt2 decreases PEPCK1-UBR5-C binding but
overexpression P300 increases the binding. Myc-PEPCK1 and UBR5-C-C/A were
expressed and purified from HEK293T cells or HEK293T co-expressing either Sirt2 or
P300, interaction between PEPCK1 and UBR5-C-C/A were analyzed by the amount of
PEPCK1 co-immunoprecipitated with UBR5-C-C/A. (F) Sirt2 increases ubiquitination level
of PEPCK1. Flag-PEPCK1, HA-Ub and Myc-Sirt2 or its catalytic mutants were co-
expressed in HEK293T cells. PEPCK1 was purified by IP. Ubiquitination level of PEPCK1
was probed by anti-HA antibody. (G) Sirtinol increases the ubiquitination level of PEPCK1.
Flag-PEPCK1 and HA-Ub were co-expressed in HEK293T cells maintained under different
concentrations of Sirtinol. IP purified PEPCK1 ubiquitination levels were detected. (H)
Sirtinol decreases steady state PEPCK protein level. HEK293T cells were cultured at
different concentrations of Sirtinol. Steady state cellular PEPCK1 level as well as PEPCK1
gene transcription level was determined. See also Figure S3.
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Figure 6. PEPCK1 degradation is controlled by glucose level and can be manipulated by control
degradation related factors
(A)-(C), results are average values of triplicate q-RT-PCR assays with SDs. (A) P300
transcription is unregulated by glucose. P300 mRNA levels of 293T cells cultured under
different glucose concentrations were determined. (B) Sirt2 transcription is down regulated
by glucose. Sirt2 mRNA levels of 293T cells cultured under different glucose concentrations
were determined. (C) Fasting reduces Sirt2 transcription. Sirt2 mRNA levels of mice liver
cells were determined. (D) PEPCK1 ubiquitination response to glucose concentration. Flag-
tagged PEPCK1 co-expressed with HA tagged ubiquitin in HEK293T cells maintained
under various glucose concentrations were purified by IP and ubiquitination of purified
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proteins were determined by anti-HA antibody. (E)-(H), Secreted glucose levels of cells
maintained in glucose free medium under conditions as indicated. Shown are average values
of triplicate measurements with SDs. (E) Overexpression of UBR5-C decreases glucose
production. HEK293T cells and HEK293T cells overexpressing UBR5-C and UBR5-C-C/A
were analyzed. (F) UBR5 knockdown increases glucose production. Chang’s cells and
Chang’s cells with UBR5 knocked down by siRNA were analyzed. (G) P300 knockdown
increases glucose production. HEK293T cells and HEK293T cells with P300 knocked down
by siRNA were analyzed. (H) Sirt2 knockdown decreases glucose production. HEK293T
cells and HEK293T cells with Sirt2 knocked down by siRNA were analyzed. (I) Sirt2
knockdown decrease PEPCK1 and gluconeogenic rate in mice. Mice were tail vein injected
by Sirt2 shRNA. Liver PEPCK1 level and blood glucose concentrations were measured.
Shown are representative PEPCK1 protein levels and average blood concentrations with SD
(n=4). See also Figure S4.
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